JP6700203B2 - ボロン酸誘導体およびその治療的使用 - Google Patents
ボロン酸誘導体およびその治療的使用 Download PDFInfo
- Publication number
- JP6700203B2 JP6700203B2 JP2016575893A JP2016575893A JP6700203B2 JP 6700203 B2 JP6700203 B2 JP 6700203B2 JP 2016575893 A JP2016575893 A JP 2016575893A JP 2016575893 A JP2016575893 A JP 2016575893A JP 6700203 B2 JP6700203 B2 JP 6700203B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CCC1CCCC1 Chemical compound *CCC1CCCC1 0.000 description 8
- ARZUMMLUZDAIAU-ZDUSSCGKSA-N COc1ccc(C[C@@H](B(O)O2)Sc3nnc(SCCN4CCNCC4)[s]3)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)Sc3nnc(SCCN4CCNCC4)[s]3)c2c1C(O)=O ARZUMMLUZDAIAU-ZDUSSCGKSA-N 0.000 description 2
- REBMDVNAJPVARL-LURJTMIESA-N OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1Sc1nnc(C(F)(F)F)[s]1 Chemical compound OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1Sc1nnc(C(F)(F)F)[s]1 REBMDVNAJPVARL-LURJTMIESA-N 0.000 description 2
- WIILWRPJAVDLOL-UHFFFAOYSA-N CC(/S=C1/Cc2cccc(C(O)=O)c2OB1O)=N Chemical compound CC(/S=C1/Cc2cccc(C(O)=O)c2OB1O)=N WIILWRPJAVDLOL-UHFFFAOYSA-N 0.000 description 1
- WPGLRFGDZJSQGI-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1N)=O Chemical compound CC(C)(C)OC(N(C1)CC1N)=O WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 1
- YEQMQPWKRCNFRO-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1NC(SC)=S)=O Chemical compound CC(C)(C)OC(N(C1)CC1NC(SC)=S)=O YEQMQPWKRCNFRO-UHFFFAOYSA-N 0.000 description 1
- GPEWAEMBWUBOTF-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Nc1nnc(S)[s]1)=O Chemical compound CC(C)(C)OC(N(C1)CC1Nc1nnc(S)[s]1)=O GPEWAEMBWUBOTF-UHFFFAOYSA-N 0.000 description 1
- OPTCHSMAUQAOEX-UHFFFAOYSA-N CCC(O1)=C(C)OC1=O Chemical compound CCC(O1)=C(C)OC1=O OPTCHSMAUQAOEX-UHFFFAOYSA-N 0.000 description 1
- XSQJSGURQRNYDW-ZETCQYMHSA-N CO[C@H](B(O)Oc1c2C(O)=O)Cc1ccc2F Chemical compound CO[C@H](B(O)Oc1c2C(O)=O)Cc1ccc2F XSQJSGURQRNYDW-ZETCQYMHSA-N 0.000 description 1
- JFXDEZBEJRDVEY-LURJTMIESA-N COc(c(C(O)=O)c(c(C[C@@H]1Sc2nnc(N)[s]2)c2)OB1O)c2F Chemical compound COc(c(C(O)=O)c(c(C[C@@H]1Sc2nnc(N)[s]2)c2)OB1O)c2F JFXDEZBEJRDVEY-LURJTMIESA-N 0.000 description 1
- ICUJWHOWEQDPCX-SQJZIBIZSA-N COc1c(C(O)=O)c(OB([C@H](C2)SC(C3)CN3C3=NC(COc4ccc(C[C@@H](B(O)O5)Sc6nnc(C(F)(F)F)[nH]6)c5c4C(O)=O)CS3)O)c2cc1 Chemical compound COc1c(C(O)=O)c(OB([C@H](C2)SC(C3)CN3C3=NC(COc4ccc(C[C@@H](B(O)O5)Sc6nnc(C(F)(F)F)[nH]6)c5c4C(O)=O)CS3)O)c2cc1 ICUJWHOWEQDPCX-SQJZIBIZSA-N 0.000 description 1
- GOWVYGOLNMMSIY-UHFFFAOYSA-N COc1ccc(CC(B(O)O2)Sc3nc(N)n[s]3)c2c1C(O)=O Chemical compound COc1ccc(CC(B(O)O2)Sc3nc(N)n[s]3)c2c1C(O)=O GOWVYGOLNMMSIY-UHFFFAOYSA-N 0.000 description 1
- GFPUGVSUXHTYFY-MRVPVSSYSA-N COc1ccc(C[C@@H](B(O)O2)CSc3cnn[s]3)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)CSc3cnn[s]3)c2c1C(O)=O GFPUGVSUXHTYFY-MRVPVSSYSA-N 0.000 description 1
- IHCBBGWGXIIOTD-MRVPVSSYSA-N COc1ccc(C[C@@H](B(O)O2)CSc3nnc[s]3)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)CSc3nnc[s]3)c2c1C(O)=O IHCBBGWGXIIOTD-MRVPVSSYSA-N 0.000 description 1
- SNASLOXHVKKQND-VIFPVBQESA-N COc1ccc(C[C@@H](B(O)O2)Sc3cnc[s]3)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)Sc3cnc[s]3)c2c1C(O)=O SNASLOXHVKKQND-VIFPVBQESA-N 0.000 description 1
- GVQZVCLRKSVJQE-QMMMGPOBSA-N COc1ccc(C[C@@H](B(O)O2)Sc3nnc(CN)[n]3N)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)Sc3nnc(CN)[n]3N)c2c1C(O)=O GVQZVCLRKSVJQE-QMMMGPOBSA-N 0.000 description 1
- FTBQGGGPAATUGP-LBPRGKRZSA-N COc1ccc(C[C@@H](B(O)O2)Sc3nnc(CN4CCNCC4)[n]3N)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)Sc3nnc(CN4CCNCC4)[n]3N)c2c1C(O)=O FTBQGGGPAATUGP-LBPRGKRZSA-N 0.000 description 1
- KXVAAHBWCIRPPN-LBPRGKRZSA-N COc1ccc(C[C@@H](B(O)O2)Sc3nnc(NCCNC4CNC4)[s]3)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)Sc3nnc(NCCNC4CNC4)[s]3)c2c1C(O)=O KXVAAHBWCIRPPN-LBPRGKRZSA-N 0.000 description 1
- JZYCXVYMCMHJQN-QMMMGPOBSA-N COc1ccc(C[C@@H](B(O)O2)Sc3nnc(SCC(N)=N)[s]3)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)Sc3nnc(SCC(N)=N)[s]3)c2c1C(O)=O JZYCXVYMCMHJQN-QMMMGPOBSA-N 0.000 description 1
- IGHZKWFWYONCMS-ZDUSSCGKSA-N COc1ccc(C[C@@H](B(O)O2)Sc3nnc(SCCN4CCOCC4)[s]3)c2c1C(O)=O Chemical compound COc1ccc(C[C@@H](B(O)O2)Sc3nnc(SCCN4CCOCC4)[s]3)c2c1C(O)=O IGHZKWFWYONCMS-ZDUSSCGKSA-N 0.000 description 1
- IXRSTFJNAHTDPU-MRVPVSSYSA-N CSc1ccc(C[C@@H](B(O)O2)CSc3nnc[n]3N)c2c1C(O)=O Chemical compound CSc1ccc(C[C@@H](B(O)O2)CSc3nnc[n]3N)c2c1C(O)=O IXRSTFJNAHTDPU-MRVPVSSYSA-N 0.000 description 1
- ZQCVSACVVSLEBV-QMMMGPOBSA-N C[n]1c(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)nnc1 Chemical compound C[n]1c(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)nnc1 ZQCVSACVVSLEBV-QMMMGPOBSA-N 0.000 description 1
- KQIGSWPJXOPGGH-QMMMGPOBSA-N N#CCS[C@H](B(O)Oc1c2C(O)=O)Cc1ccc2F Chemical compound N#CCS[C@H](B(O)Oc1c2C(O)=O)Cc1ccc2F KQIGSWPJXOPGGH-QMMMGPOBSA-N 0.000 description 1
- RDGXHFRUQUNGAN-ZETCQYMHSA-N NC(CS[C@H](B(O)Oc1c2C(O)=O)Cc1ccc2F)=O Chemical compound NC(CS[C@H](B(O)Oc1c2C(O)=O)Cc1ccc2F)=O RDGXHFRUQUNGAN-ZETCQYMHSA-N 0.000 description 1
- AJMCDBKATZBNHS-QMMMGPOBSA-N NC(c1cnc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1)=O Chemical compound NC(c1cnc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1)=O AJMCDBKATZBNHS-QMMMGPOBSA-N 0.000 description 1
- UBZDLTZSIBMTQJ-VIFPVBQESA-N NCCSc1nnc(S[C@H]2Cc3cccc(C(O)=O)c3OB2O)[s]1 Chemical compound NCCSc1nnc(S[C@H]2Cc3cccc(C(O)=O)c3OB2O)[s]1 UBZDLTZSIBMTQJ-VIFPVBQESA-N 0.000 description 1
- QGAWUTJNTSYULE-VIFPVBQESA-N NCc1cnc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 Chemical compound NCc1cnc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 QGAWUTJNTSYULE-VIFPVBQESA-N 0.000 description 1
- BMVQNYKVSHHBFR-ZETCQYMHSA-N N[n]1c(S[C@H]2Cc(ccc(F)c3C(O)=O)c3OB2O)nnc1 Chemical compound N[n]1c(S[C@H]2Cc(ccc(F)c3C(O)=O)c3OB2O)nnc1 BMVQNYKVSHHBFR-ZETCQYMHSA-N 0.000 description 1
- WMSFSMPRPNIWDD-QMMMGPOBSA-N N[n]1c(S[C@H]2Cc3cccc(C(O)=O)c3OB2O)nnc1 Chemical compound N[n]1c(S[C@H]2Cc3cccc(C(O)=O)c3OB2O)nnc1 WMSFSMPRPNIWDD-QMMMGPOBSA-N 0.000 description 1
- JYNVMYRYEYYHCX-ZETCQYMHSA-N Nc1ncc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 Chemical compound Nc1ncc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 JYNVMYRYEYYHCX-ZETCQYMHSA-N 0.000 description 1
- DVCOUFYAYPANSK-UHFFFAOYSA-N Nc1nnc(CCSC(B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 Chemical compound Nc1nnc(CCSC(B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 DVCOUFYAYPANSK-UHFFFAOYSA-N 0.000 description 1
- DVCOUFYAYPANSK-QMMMGPOBSA-N Nc1nnc(CCS[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 Chemical compound Nc1nnc(CCS[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 DVCOUFYAYPANSK-QMMMGPOBSA-N 0.000 description 1
- GWSDAQZCKOLKMJ-LURJTMIESA-N Nc1nnc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 Chemical compound Nc1nnc(S[C@H](B(O)Oc2c3C(O)=O)Cc2ccc3F)[s]1 GWSDAQZCKOLKMJ-LURJTMIESA-N 0.000 description 1
- MDFYRHMTCKYBKU-MRVPVSSYSA-N OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1CSc1ncc(NC=O)[s]1 Chemical compound OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1CSc1ncc(NC=O)[s]1 MDFYRHMTCKYBKU-MRVPVSSYSA-N 0.000 description 1
- RBGQRSWYVGULBU-ZETCQYMHSA-N OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1Sc1cnn[s]1 Chemical compound OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1Sc1cnn[s]1 RBGQRSWYVGULBU-ZETCQYMHSA-N 0.000 description 1
- KJTIZQKAMZFMTQ-ZETCQYMHSA-N OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1Sc1nnc[s]1 Chemical compound OB1Oc2c(C(O)=O)c(F)ccc2C[C@@H]1Sc1nnc[s]1 KJTIZQKAMZFMTQ-ZETCQYMHSA-N 0.000 description 1
- DVBZVPCWWAVOBE-UHFFFAOYSA-N OC(c(cccc1CC2OCc3ccccc3)c1OS2O)=O Chemical compound OC(c(cccc1CC2OCc3ccccc3)c1OS2O)=O DVBZVPCWWAVOBE-UHFFFAOYSA-N 0.000 description 1
- AZJTXDQIEKEPCH-UHFFFAOYSA-N OC(c(cccc1CC2Sc3ncc[s]3)c1OS2O)=O Chemical compound OC(c(cccc1CC2Sc3ncc[s]3)c1OS2O)=O AZJTXDQIEKEPCH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462019758P | 2014-07-01 | 2014-07-01 | |
| US62/019,758 | 2014-07-01 | ||
| PCT/US2015/038364 WO2016003929A1 (en) | 2014-07-01 | 2015-06-29 | Boronic acid derivatives and therapeutic uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526636A JP2017526636A (ja) | 2017-09-14 |
| JP2017526636A5 JP2017526636A5 (enExample) | 2018-09-06 |
| JP6700203B2 true JP6700203B2 (ja) | 2020-05-27 |
Family
ID=55019887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575893A Active JP6700203B2 (ja) | 2014-07-01 | 2015-06-29 | ボロン酸誘導体およびその治療的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10206937B2 (enExample) |
| EP (1) | EP3164406B1 (enExample) |
| JP (1) | JP6700203B2 (enExample) |
| KR (1) | KR20170024087A (enExample) |
| CN (1) | CN106536529B (enExample) |
| AU (1) | AU2015284307A1 (enExample) |
| CA (1) | CA2952968A1 (enExample) |
| EA (1) | EA201692301A1 (enExample) |
| MX (1) | MX2016016666A (enExample) |
| WO (1) | WO2016003929A1 (enExample) |
| ZA (1) | ZA201608682B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60310B1 (sr) | 2010-08-10 | 2020-07-31 | Rempex Pharmaceuticals Inc | Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe |
| EP2941246A4 (en) | 2013-01-04 | 2016-12-21 | Rempex Pharmaceuticals Inc | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES |
| CN105101970B (zh) * | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| SMT201900611T1 (it) | 2014-05-05 | 2020-01-14 | Rempex Pharmaceuticals Inc | Sintesi di sali boronati e usi degli stessi |
| ES2985626T3 (es) | 2014-05-05 | 2024-11-06 | Melinta Therapeutics Inc | Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos |
| CN106459096B (zh) | 2014-05-19 | 2019-03-08 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| ES2874579T3 (es) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2016149393A1 (en) * | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10399996B2 (en) | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN106008446A (zh) * | 2016-04-29 | 2016-10-12 | 广州药本君安医药科技股份有限公司 | 呫吨酮衍生物及呫吨酮和其衍生物的制备方法与用途 |
| DK3478693T3 (da) * | 2016-06-30 | 2021-09-20 | Qpex Biopharma Inc | Boronsyrederivater og terapeutiske anvendelser deraf |
| FR3053968A1 (fr) | 2016-07-13 | 2018-01-19 | Biomerieux | Reactifs pour la protection reversible de molecules biologiques |
| US10889600B2 (en) | 2016-08-04 | 2021-01-12 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| GB201613946D0 (en) | 2016-08-15 | 2016-09-28 | Univ Oslo | Compounds |
| JOP20190188A1 (ar) | 2017-02-01 | 2019-08-01 | Rempex Pharmaceuticals Inc | جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك |
| WO2018199291A1 (ja) * | 2017-04-28 | 2018-11-01 | 大日本住友製薬株式会社 | ヘテロ環誘導体 |
| EP3630782A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| TW201906616A (zh) * | 2017-07-06 | 2019-02-16 | 日商大日本住友製藥股份有限公司 | 醯胺衍生物 |
| WO2019009369A1 (ja) * | 2017-07-06 | 2019-01-10 | 大日本住友製薬株式会社 | イミン誘導体 |
| JP7377545B2 (ja) | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ， インコーポレイテッド | ボロン酸誘導体およびその合成 |
| AU2019256351B2 (en) | 2018-04-20 | 2024-02-29 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN118638140A (zh) * | 2018-04-27 | 2024-09-13 | 住友制药株式会社 | 氧代取代化合物 |
| EP3802551A4 (en) | 2018-05-25 | 2022-03-02 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| TW202123945A (zh) * | 2019-09-13 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 具有抗菌作用的醫藥組成物 |
| JP7550421B2 (ja) * | 2019-10-25 | 2024-09-13 | 住友ファーマ株式会社 | オキソ置換化合物からなる医薬 |
| EP4049680A4 (en) | 2019-10-25 | 2024-01-10 | Sumitomo Pharma Co., Ltd. | NEW SUBSTITUTED CONDENSED RING CONNECTION |
| CN110938015B (zh) * | 2019-12-06 | 2022-10-25 | 重庆工商大学 | 一种叠氮基取代的水杨酸衍生物的制备方法 |
| DK4069691T3 (da) | 2019-12-06 | 2024-10-28 | Vertex Pharma | Substituerede tetrahydrofuraner som modulatorer af natriumkanaler |
| CN113150022B (zh) * | 2021-04-23 | 2022-12-06 | 四川大学 | 3-取代五元环状硼酸酯衍生物及其药物组合物和制药用途 |
| US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| CN117343088A (zh) * | 2022-07-05 | 2024-01-05 | 福安药业集团重庆三禾兴医药科技有限公司 | 一类7-((五元杂环)甲基)-8-羧酸-苯并环硼酸酯类衍生物及其用途 |
| US20250099495A1 (en) * | 2023-09-22 | 2025-03-27 | City University Of Hong Kong | Methods of inhibiting klebsiella pneumoniae carbapenemase-2 |
| WO2025119216A1 (zh) * | 2023-12-04 | 2025-06-12 | 珠海联邦制药股份有限公司 | 硼酸类β-内酰胺酶抑制剂及其制备方法和应用 |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3686398A (en) | 1970-07-20 | 1972-08-22 | Chevron Res | 10,9-boroxarophenanthrene as fungicides |
| US4194047A (en) | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
| US4260543A (en) | 1978-07-03 | 1981-04-07 | Merck & Co., Inc. | Crystalline N-formimidoyl thienamycin |
| US4409214A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
| US4353807A (en) | 1981-03-24 | 1982-10-12 | Mobil Oil Corporation | Lubricants and fuels containing boroxarophenanthrene compounds |
| FR2573070B1 (fr) * | 1984-11-13 | 1987-01-30 | Rhone Poulenc Sante | Procede de preparation de composes carbonyles |
| US4758557A (en) | 1985-06-26 | 1988-07-19 | Meiji Seika Kaisha, Ltd. | Cephalosporin derivatives and bactericides containing the same |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| CA1283404C (en) | 1986-07-01 | 1991-04-23 | Shigeru Sanai | Cephalosporin compounds, processes for their preparation and antibacterial agents |
| US5028601A (en) | 1987-04-30 | 1991-07-02 | Meiji Saika Kaisha, Ltd. | Cephalosporin compounds and antibacterial agents |
| EP0333082A3 (en) | 1988-03-15 | 1991-05-02 | Takeda Chemical Industries, Ltd. | Cephem compounds, their production and use |
| ZA893284B (en) | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
| US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
| GB9601680D0 (en) | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
| US5888998A (en) | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
| WO1998056392A1 (en) | 1997-06-13 | 1998-12-17 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| WO2000035905A1 (en) | 1998-12-16 | 2000-06-22 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| AU3124300A (en) | 1998-12-16 | 2000-07-03 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
| WO2000040571A1 (en) | 1999-01-02 | 2000-07-13 | Aventis Pharma Deutschland Gmbh | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) |
| AU765020B2 (en) | 1999-09-25 | 2003-09-04 | Smithkline Beecham Plc | Piperazine derivatives as 5-HT1B antagonists |
| AU762935B2 (en) | 1999-10-28 | 2003-07-10 | Merck & Co., Inc. | Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| WO2002022137A1 (en) | 2000-09-12 | 2002-03-21 | Shoichet Brian K | β-LACTAM ANALOGS AND USES THEREFOR |
| AU2002212614B2 (en) | 2000-09-14 | 2006-12-07 | Basilea Pharmaceutica Ag | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| US6586615B1 (en) | 2001-01-10 | 2003-07-01 | Bristol-Myers Squibb Company | α-aminoboronic acids prepared by novel synthetic methods |
| DE10118698A1 (de) | 2001-04-17 | 2002-11-07 | Jerini Ag | Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche |
| WO2003057144A2 (en) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| JP2003229277A (ja) | 2002-02-04 | 2003-08-15 | Matsushita Electric Ind Co Ltd | 発光素子材料およびそれを用いた発光素子並びに装置 |
| AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
| JP3714948B2 (ja) | 2002-09-11 | 2005-11-09 | 呉羽化学工業株式会社 | アミン化合物及びその用途 |
| WO2004039859A1 (ja) | 2002-10-30 | 2004-05-13 | Sumitomo Chemical Company, Limited | 高分子化合物およびそれを用いた高分子発光素子 |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| EP1581472A2 (en) | 2002-12-20 | 2005-10-05 | MIGENIX Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| ES2401911T3 (es) | 2003-03-24 | 2013-04-25 | Axikin Pharmaceuticals, Inc. | Derivados de 2-fenoxi- y 2-fenilsulfanil-bencenosulfonamida con actividad antagonista de CCR3 para el tratamiento de asma y otras alteraciones inflamatorias o inmunológicas |
| JP4233365B2 (ja) | 2003-03-25 | 2009-03-04 | 三井化学株式会社 | アザジオール錯体化合物、及び該化合物を用いる光記録媒体 |
| CA2530014A1 (en) | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| JP2005089383A (ja) | 2003-09-18 | 2005-04-07 | Bayer Cropscience Ag | 新規チアジアゾール含有ジフルオロアルケン類及び有害生物防除剤としての利用 |
| US7842941B2 (en) | 2003-10-06 | 2010-11-30 | Sumitomo Chemical Company, Limited | Aromatic compound |
| WO2005035532A1 (en) | 2003-10-10 | 2005-04-21 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
| EP1743676A1 (en) | 2003-11-12 | 2007-01-17 | Phenomix Corporation | Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors |
| TW200600494A (en) | 2004-03-08 | 2006-01-01 | Chugai Pharmaceutical Co Ltd | Bisphenyl compounds useful as vitamin d3 receptor agonists |
| US20060019116A1 (en) | 2004-07-22 | 2006-01-26 | Eastman Kodak Company | White electroluminescent device with anthracene derivative host |
| TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| US20060178357A1 (en) | 2005-02-10 | 2006-08-10 | Buynak John D | Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases |
| ES2872962T3 (es) | 2005-02-16 | 2021-11-03 | Anacor Pharmaceuticals Inc | Boronoftalidas para uso terapéutico |
| MX2007010138A (es) | 2005-02-22 | 2007-09-27 | Teva Pharma | Preparacion de rosuvastatina. |
| US9184428B2 (en) | 2005-03-15 | 2015-11-10 | Uchicago Argonne Llc | Non-aqueous electrolytes for lithium ion batteries |
| KR100648133B1 (ko) | 2005-04-25 | 2006-11-23 | 일동제약주식회사 | 펩티드 데포르밀라제 저해제로서 신규의 히드록사믹 산유도체 및 그 제조방법 |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| CA2629570C (en) | 2005-12-07 | 2012-11-27 | Basilea Pharmaceutica Ag | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors |
| CN101420854B (zh) | 2006-02-16 | 2013-08-07 | 安纳考尔医药公司 | 作为抗炎药的含硼的小分子 |
| AU2007300531A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Novel inhibitors of beta-lactamase |
| WO2008116813A2 (en) | 2007-03-23 | 2008-10-02 | Basilea Pharmaceutica Ag | Combination medicaments for treating bacterial infections |
| GB0719366D0 (en) | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
| US20100120715A1 (en) * | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| AU2008321443A1 (en) * | 2007-11-13 | 2009-05-22 | Novartis Ag | Beta-lactamase inhibitors |
| MY162532A (en) | 2008-01-18 | 2017-06-15 | Merck Sharp & Dohme | Beta-lactamase inhibitors |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20110039895A1 (en) | 2008-04-30 | 2011-02-17 | Glaxo Smith Kline LLC., a corporation | Prolyl hydroxylase inhibitors |
| US20100256092A1 (en) | 2008-05-12 | 2010-10-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2009139834A1 (en) | 2008-05-13 | 2009-11-19 | Poniard Pharmaceuticals, Inc. | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| WO2010030811A2 (en) | 2008-09-10 | 2010-03-18 | Achaogen, Inc. | CARBACEPHEM β-LACTAM ANTIBIOTICS |
| US20120046242A1 (en) | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
| WO2010097675A1 (en) | 2009-02-27 | 2010-09-02 | Dhanuka Laboratories Ltd. | An improved preparation process for cefpodoxime proxetil |
| AR076667A1 (es) | 2009-05-12 | 2011-06-29 | Novartis Int Pharm Ltd | Inhibidores de beta-lactamasa |
| EP2440050A4 (en) | 2009-06-08 | 2013-04-03 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION |
| EP2458995A1 (en) | 2009-07-28 | 2012-06-06 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
| CN102153553A (zh) | 2010-02-11 | 2011-08-17 | 山东轩竹医药科技有限公司 | 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物 |
| CA2828114A1 (en) | 2010-02-26 | 2011-09-01 | Gary Igor DMITRIENKO | Cephalosporin derivatives useful as .beta.-lactamase inhibitors and compositions and methods of use thereof |
| AR080863A1 (es) * | 2010-03-31 | 2012-05-16 | Millennium Pharm Inc | Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. |
| FR2959061B1 (fr) | 2010-04-20 | 2012-05-11 | Commissariat Energie Atomique | Substrat fonctionnalise et ses applications |
| US20110288063A1 (en) | 2010-05-19 | 2011-11-24 | Naeja Pharmaceutical Inc. | Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors |
| WO2011154953A1 (en) | 2010-06-10 | 2011-12-15 | Technion R&D Foundation Ltd. | Process for the preparation of iodides |
| RS60310B1 (sr) | 2010-08-10 | 2020-07-31 | Rempex Pharmaceuticals Inc | Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe |
| BR112013010099B1 (pt) | 2010-10-26 | 2021-08-10 | Mars, Incorporated | Boronatos como inibidores de arginase |
| TW201221518A (en) | 2010-11-18 | 2012-06-01 | Glaxo Group Ltd | Compounds |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| EP2508506A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
| WO2013033461A1 (en) * | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2013053372A1 (en) * | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| WO2013056163A1 (en) | 2011-10-14 | 2013-04-18 | The Regents Of The University Of California | Beta-lactamase inhibitors |
| ITTO20111013A1 (it) | 2011-11-03 | 2013-05-04 | Dac Srl | Composti farmaceutici |
| HK1206261A1 (en) * | 2011-12-22 | 2016-01-08 | Ares Trading S.A. | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| CA2862710A1 (en) * | 2012-01-09 | 2013-07-18 | University Of Tromso | Therapeutic boron-containing compounds |
| EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
| WO2013122888A2 (en) * | 2012-02-15 | 2013-08-22 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| WO2013160810A2 (en) | 2012-04-24 | 2013-10-31 | Hetero Research Foundation | Novel betulinic acid derivatives as hiv inhibitors |
| US9309284B2 (en) | 2012-05-02 | 2016-04-12 | Kansas State University Reasearch Foundation | Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses |
| US9156858B2 (en) * | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2013174931A1 (en) | 2012-05-23 | 2013-11-28 | Savira Pharmaceuticals Gmbh | 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| AU2013355110B2 (en) * | 2012-12-07 | 2017-11-09 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP2941246A4 (en) * | 2013-01-04 | 2016-12-21 | Rempex Pharmaceuticals Inc | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CA2894892A1 (en) * | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US8999885B2 (en) | 2013-01-09 | 2015-04-07 | General Electric Company | Methods of activating charcoal resulting from biomass gasification |
| CN105101970B (zh) | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| AU2014232764A1 (en) | 2013-03-15 | 2015-10-08 | Zhengyu Long | Novel cyclosporin derivatives and uses thereof |
| SMT201900611T1 (it) | 2014-05-05 | 2020-01-14 | Rempex Pharmaceuticals Inc | Sintesi di sali boronati e usi degli stessi |
| ES2985626T3 (es) | 2014-05-05 | 2024-11-06 | Melinta Therapeutics Inc | Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos |
| CN106459096B (zh) * | 2014-05-19 | 2019-03-08 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2016065282A1 (en) | 2014-10-24 | 2016-04-28 | The Regents Of The University Of Michigan | Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels |
| AU2016252555A1 (en) | 2015-04-24 | 2017-11-09 | Melinta Therapeutics, Inc. | Methods of treating bacterial infections |
-
2015
- 2015-06-29 MX MX2016016666A patent/MX2016016666A/es unknown
- 2015-06-29 CN CN201580039809.8A patent/CN106536529B/zh active Active
- 2015-06-29 EA EA201692301A patent/EA201692301A1/ru unknown
- 2015-06-29 JP JP2016575893A patent/JP6700203B2/ja active Active
- 2015-06-29 US US15/323,081 patent/US10206937B2/en active Active
- 2015-06-29 AU AU2015284307A patent/AU2015284307A1/en not_active Abandoned
- 2015-06-29 CA CA2952968A patent/CA2952968A1/en not_active Abandoned
- 2015-06-29 KR KR1020177002769A patent/KR20170024087A/ko not_active Withdrawn
- 2015-06-29 EP EP15815718.0A patent/EP3164406B1/en active Active
- 2015-06-29 WO PCT/US2015/038364 patent/WO2016003929A1/en not_active Ceased
-
2016
- 2016-12-15 ZA ZA2016/08682A patent/ZA201608682B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3164406C0 (en) | 2024-12-25 |
| EP3164406A4 (en) | 2018-04-04 |
| EA201692301A1 (ru) | 2017-06-30 |
| JP2017526636A (ja) | 2017-09-14 |
| MX2016016666A (es) | 2017-08-08 |
| AU2015284307A1 (en) | 2017-02-02 |
| CA2952968A1 (en) | 2016-01-07 |
| CN106536529B (zh) | 2019-09-27 |
| US20170136047A1 (en) | 2017-05-18 |
| WO2016003929A1 (en) | 2016-01-07 |
| EP3164406B1 (en) | 2024-12-25 |
| US10206937B2 (en) | 2019-02-19 |
| EP3164406A1 (en) | 2017-05-10 |
| KR20170024087A (ko) | 2017-03-06 |
| CN106536529A (zh) | 2017-03-22 |
| ZA201608682B (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6700203B2 (ja) | ボロン酸誘導体およびその治療的使用 | |
| US12509475B2 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| JP6324409B2 (ja) | ボロン酸誘導体及びその治療的使用 | |
| JP6672176B2 (ja) | ボロン酸誘導体およびその治療的使用 | |
| US10618918B2 (en) | Substituted boronic acids as antimicrobials | |
| US9101638B2 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| AU2014204045B2 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| US9241947B2 (en) | Boronic acid derivatives and therapeutic uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170113 |
|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170228 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170113 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180625 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180723 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190215 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190513 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191122 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200414 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200430 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6700203 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |